Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

PRA Health Sciences to Report Third Quarter 2016 Earnings

RALEIGH, N.C., Oct. 10, 2016 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:PRAH) will release its third quarter 2016 results after the market closes on Wednesday, November 2. The Company will also host a conference call on Thursday, November 3 at 9:00 a.m. (ET) to discuss the results with members of the investment community.

To participate via telephone, investors and analysts should dial (877) 930-8062 within the United States or (253) 336-7647 outside the United States approximately 10 minutes prior to the call start time. The conference ID for the call is 97800997. An audio replay of the call will be available for one week following the call and can be accessed by dialing (855) 859-2056 within the United States or (404) 537-3406 outside the United States. The replay ID is 97800997.

A live audio broadcast will be available on the investor relations section of the PRA Health Sciences website. Following the teleconference, the presentation and an audio playback of the call will be available at the same website.

ABOUT PRA HEALTH SCIENCES

PRA is one of the world's leading global contract research organizations, by revenue, providing outsourced clinical development services to the biotechnology and pharmaceutical industries. PRA’s global clinical development platform includes approximately 70 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East, and approximately 12,000 employees worldwide. Since 2000, PRA has performed approximately 3,300 clinical trials worldwide and has worked on more than 100 marketed drugs across several therapeutic areas. In addition, PRA has participated in the pivotal or supportive trials that led to U.S. Food and Drug Administration or international regulatory approval of more than 60 drugs. To learn more about PRA, please visit www.prahs.com.

CONTACTS: Luke Heagle Pure Communications, Inc. Director, Investor Relations 910.726.1372 InvestorRelations@PRAHS.com or luke@purecommunicationsinc.com Christine Rogers PRA Health Sciences, Inc. Director, Public Relations 919.786.8463 rogerschristine@prahs.com

Primary Logo

Tags:


Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today